The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.
- 1 February 1991
- journal article
- clinical trial
- Published by BMJ in Sexually Transmitted Infections
- Vol. 67 (1) , 15-17
- https://doi.org/10.1136/sti.67.1.15
Abstract
Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.Keywords
This publication has 9 references indexed in Scilit:
- The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) InfectionAnnals of Internal Medicine, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Clinical Pharmacology of 3'-Azido-2',3'-Dideoxythymidine (Zidovudine) and Related DideoxynucleosidesNew England Journal of Medicine, 1989
- Nature, time course and dose dependence of zidovudine-related side effectsAIDS, 1989
- Effect of Zidovudine on Serum Human Immunodeficiency Virus Core Antigen LevelsArchives of internal medicine (1960), 1988
- Anemia and Erythropoiesis in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and Kaposi Sarcoma Treated with ZidovudineAnnals of Internal Medicine, 1988
- EFFECT OF ZIDOVUDINE ON SERUM HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN LEVELS IN SYMPTOM-FREE SUBJECTSThe Lancet, 1988
- Human Immunodeficiency Virus (HIV) Antigenemia (p24) in the Acquired Immunodeficiency Syndrome (AIDS) and the Effect of Treatment with Zidovudine (AZT)Annals of Internal Medicine, 1988
- Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.BMJ, 1986